Recommendations for the diagnosis and treatment of Sj?gren′s syndrome in China
10.3760/cma.j.cn112138-20221027-00797
- VernacularTitle:原发性干燥综合征诊疗规范
- Author:
Wen ZHANG
1
;
Zhu CHEN
;
Xiaomei LI
;
Jie GAO
;
Yan ZHAO
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院风湿免疫科 国家皮肤与免疫疾病临床医学研究中心 疑难重症和罕见病国家重点实验室 风湿免疫病教育部重点实验室，北京 100730
- Keywords:
Sj?gren′s syndrome;
Diagnosis;
Treatment;
Prognosis
- From:
Chinese Journal of Internal Medicine
2023;62(9):1059-1067
- CountryChina
- Language:Chinese
-
Abstract:
Sj?gren′s syndrome (SS) is a chronic systemic autoimmune disease characterized by lymphocyte proliferation and progressive exocrine gland damage. In addition to the impairment of salivary and lacrimal gland function, SS can present with multi-system and multi-organ involvement, accompanied by autoantibodies in serum and hyperimmunoglobulinemia. SS can be divided into primary and secondary forms based on the absence or presence, respectively, of concurrent connective tissue diseases such as systemic lupus erythematosus and rheumatoid arthritis. Based on evidence and guidelines from China and other countries, the Chinese Rheumatology Association drafted standardized criteria for the diagnosis and treatment of primary SS. The objectives were to standardize the detection and interpretation of key indicators for the diagnosis of SS, including serum anti-SSA antibody and labial gland pathology, suggest the use of the widely accepted European League Against Rheumatism (EULAR)-SS disease activity index for the evaluation of the disease, and standardize the rational management of SS patients with topical and systemic therapies.
